se outcomes in our
outstanding litigation or an increase in the number of litigation matters
to which we are subject; government regulation affecting the development,
manufacture, marketing and sale of pharmaceutical products, including our
ability and the ability of companies with whom we do business to obtain
necessary regulatory approvals; our ability to manage the growth of our
business by successfully identifying, developing, acquiring or licensing
new products at favorable prices and marketing such new products; our
ability to obtain regulatory approval and customer acceptance of new
products, and continued customer acceptance of our existing products;
changes in tax laws or interpretations that could increase our consolidated
tax liabilities; the other risks identified in our Annual Report on Form
10-K for the year ended December 31, 2007; and other risks detailed from
time-to-time in our public filings, financial statements and other investor
communications.
We caution you that the foregoing list of important factors is not
exclusive. In addition, in light of these risks and uncertainties, the
matters referred to in our forward-looking statements may not occur. We
undertake no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events or otherwise,
except as may be required by law.
'/>"/>SOURCE Warner Chilcott Limited Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors2.
CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN3.
Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner4.
Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director5.
Warner Chilcott Announces 2008 Financial Guidance6.
Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference7.
Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference8.
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 20079.
Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction10.
Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco11.
SXC Health Solutions announces completion of exchange offer for NMHC